1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Marksans Pharma Limited

Marksans Pharma Limited

MARKSANS.NS
Marksans Pharma LimitedIN flagNational Stock Exchange of India
242.37
INR
+1.18
- -
109.83BMarket Cap
Marksans Pharma Limited
MARKSANS.NS
(National Stock Exchange of India)

Recent

price

242.37

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
8.28
9.67
11.38
16.31
19.46
21.58
18.54
22.09
24.12
27.59
33.43
36.16
44.53
47.98
57.89
65.11
65.19
Revenue per Share
-0.04
-4.86
1.19
1.87
2.67
1.92
0.22
0.87
1.97
2.95
5.83
4.51
6.41
6.92
8.4
9.22
9.23
Basic EPS, GAAP
-1.42
-1.84
1
1.55
2.88
-2.47
-0.33
1.22
0.67
4.24
3.23
1.29
4.42
0.48
0.74
7.23
- -
Free Cash Flow per Basic Share
- -
0.01
0.12
0.27
0.17
0.44
0.42
0.06
0.11
0.72
0.1
0.26
0.24
0.5
0.6
0.8
- -
Dividend per Share
1.37
-8.33
-6.84
-5.59
-2.42
-1.17
-1.41
-0.69
1.07
3.08
9.18
13.44
19.81
24.59
32.39
1
1
Book Value per Share
-7.27
-6.9
0.3
1.61
7.62
8.5
7.97
9.46
11.75
14.08
20.48
27.71
39.86
43.73
52.44
63.78
63.86
Tangible Book Value per Share
368
368
385
385
409
409
409
409
409
409
409
409
415
453
453
453
453
Basic Weighted Avg Shares
3,046
3,555
4,384
6,285
7,967
8,833
7,588
9,041
9,873
11,293
13,684
14,801
18,496
21,742
26,228
29,509
29,509
Sales/Revenue/Turnover
-30.64
-34.72
12.46
15.64
20.06
11.81
0.37
5.71
11.07
14.67
23.29
14.64
16.92
17.82
17.13
17.02
17.02
Operating Margin (%)
2
237
156
157
161
281
301
268
228
267
362
448
519
743
834
986
986
Depreciation Expense
-14
-1,788
459
719
1,094
785
88
358
804
1,208
2,385
1,846
2,663
3,137
3,806
4,179
4,179
Net Income, GAAP
- -
- -
- -
14.8
28.18
22.56
23.92
28.11
22.88
23.17
21.06
24.52
21.42
25.65
24.08
25.06
25.06
Effective Tax Rate (%)
-0.46
-50.3
10.47
11.44
13.73
8.89
1.16
3.96
8.15
10.69
17.43
12.47
14.4
14.43
14.51
14.16
14.16
Profit Margin (%)
-3,104
-3,036
-534
238
2,226
1,891
1,878
2,159
2,988
3,648
6,039
8,450
13,343
14,726
17,268
21,956
21,956
Working Capital
190
152
79
198
- -
- -
- -
- -
- -
75
93
414
657
1,900
2,633
2,701
2,701
LT Debt
-626
-1,625
935
1,488
3,879
4,532
4,397
4,804
5,527
6,491
9,054
12,230
17,651
20,859
24,894
30,527
30,527
Total Equity
- -
- -
- -
28.58
26.07
15.04
0.39
6.35
13.23
18.88
29.77
13.83
14.9
13.4
13.05
11.94
11.94
Return on Invested Capital (%)
- -
- -
- -
-146.16
322.62
172.59
15.93
44.61
67.01
77.1
80.75
33.57
33
27.36
24.28
38.91
38.91
Return on Capital (%)
-2.76
- -
- -
- -
- -
- -
- -
- -
- -
142.1
95.05
39.86
38.79
32.39
29.48
55.25
55.25
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
659
- -
732
LT Borrowings
- -
- -
- -
LT Finance Leases
2,662
- -
2,701
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
453
- -
453
Market Capitalization
74,690
81,598
71,018

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
23,542
- -
27,227
Cash, Cash Equivalents & STI
6,713
- -
9,946
Accounts Receivable, Net
6,031
- -
6,446
Inventories
9,552
- -
9,723
Total Current Liabilities
4,546
- -
5,271
Payables & Accruals
- -
- -
- -
ST Debt
659
- -
732
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.78%
27.91%
22.63%
Free Cash Flow
93.78%
205.25%
870.8%
Net Income, GAAP
55.93%
14.12%
9.81%
Sales/Revenue/Turnover
13.36%
16.77%
12.51%
Total Cash Common Dividend
79.83%
66.15%
33.33%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,000
5,312
5,861
5,568
21,742
2025
5,906
6,419
6,818
7,085
26,228
2026
6,200
7,204
7,544
8,561
29,509

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.52
1.84
1.84
- -
6.92
2025
1.96
2.13
2.31
2
8.4
2026
1.29
2.17
2.5
3.27
9.22

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
0.8
Similar Companies
Clarus Therapeutics Holdings, Inc. (CRXTQ)
AbbVie Inc. (ABBV)
Sanofi (SNYNF)
Pfizer Inc. (PFE)
Psyence Group Inc. (PSYG.CN)
AstraZeneca PLC (AZN)
Business
Marksans Pharma Limited Marksans Pharma Limited engages in the research, manufacturing, marketing, and sale of generic pharmaceutical formulations, with a primary focus on over-the-counter (OTC) and prescription (Rx) products across therapeutic areas including pain management, cough and cold, gastrointestinal, cardiovascular, central nervous system, anti-diabetic, analgesics, upper respiratory, dermatology, anti-allergy, anti-fungal, and vitamins; its product portfolio encompasses plain, enteric-coated, and film-coated tablets, hard and soft gelatin capsules, oral liquids, ointments, creams, and sachets, supported by four state-of-the-art manufacturing facilities in India (Goa units with total capacity exceeding 26 billion units annually), the United Kingdom (Southport), and the United States (Farmingdale), along with four R&D centers. The company, founded in 1992 and headquartered in Mumbai, India, operates in over 50 countries, with key markets in the US (via Time-Cap Labs), UK and Europe (via Marksans Pharma UK Ltd., including Bell Sons & Co. for OTC and Relonchem for Rx), Australia and New Zealand (via Nova Pharmaceuticals), and rest-of-world regions spanning CIS and MENA, supplying leading retailers such as Walmart, Target, Walgreens, and Kroger. Recent developments include the 2023 acquisition of a Teva Pharma manufacturing facility in Goa to expand capacity to 8 billion units annually in phases (with Phase 2 completion targeted by end-FY25), the 2022 acquisition of Access Healthcare in Dubai to bolster Middle East and Africa presence, multiple USFDA and UK MHRA approvals (such as Omeprazole Delayed-Release Tablets and Loratadine Tablets in 2024-2025), over 100 products in pipeline across markets, and a strategic shift toward backward integration for API captive consumption alongside calibrated inorganic growth in Europe.